Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,243Revenue (TTM) $M66.1Net Margin (%)-5.8Altman Z-Score53.9
Enterprise Value $M804EPS (TTM) $-0.1Operating Margin %-21.8Piotroski F-Score6
P/E(ttm)--Beneish M-Score495Pre-tax Margin (%)-5.8Higher ROA y-yY
Price/Book2.910-y EBITDA Growth Rate %-33.0Quick Ratio32.9Cash flow > EarningsY
Price/Sales18.25-y EBITDA Growth Rate %-3.2Current Ratio32.9Lower Leverage y-yY
Price/Free Cash Flow4,550y-y EBITDA Growth Rate %--ROA % (ttm)-1.0Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-1.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ACHNJoel Greenblatt 2016-03-31 Buy 0.05%$5.63 - $10.79
($7.36)
$ 9.1024%New holding554,125
ACHNFirst Eagle Investment 2014-03-31 Sold Out -0.0054%$3.08 - $4.2
($3.51)
$ 9.10159%Sold Out0
ACHNFirst Eagle Investment 2013-12-31 Buy 0.01%$2.43 - $3.46
($2.9)
$ 9.10214%New holding600,000
ACHNGeorge Soros 2012-06-30 Sold Out -0.04%$5.94 - $10.95
($7.34)
$ 9.1024%Sold Out0
ACHNGeorge Soros 2012-03-31 Reduce-0.09%$7.71 - $12.375
($9.57)
$ 9.10-5%Reduce -50.00%250,000
ACHNGeorge Soros 2011-12-31 Add0.16%$4.01 - $8
($6.15)
$ 9.1048%Add 2132.14%500,000
ACHNGeorge Soros 2011-09-30 Buy $4.63 - $8.31
($6.37)
$ 9.1043%New holding22,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ACHN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-13.33view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-9.72view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-10.52view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.2210.71view
VITULLO NICOLEDirector 2015-08-14Sell37,843$7.5121.17view
Fenton Mary KayEVP and CFO 2015-01-23Sell13,125$16-43.13view
Deshpande MilindPresident and CEO 2015-01-21Sell100,000$15-39.33view
RA CAPITAL MANAGEMENT, LLC 2014-09-30Sell1,332,014$10.2-10.78view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-26Sell2,372,915$11.17-18.53view
RA CAPITAL MANAGEMENT, LLC10% Owner 2014-09-23Sell2,595,071$11.29-19.4view

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 
Achillion Pharmaceuticals Inc. Reports Operating Results (10-Q) Oct 27 2010 

More From Other Websites
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... May 27 2016
What Hedge Funds Think About Achillion Pharmaceuticals, Inc. (ACHN)? May 23 2016
Achillion Announces Acceptance of Late Breaking Abstract for ACH-4471 at the 21st Congress of the... May 19 2016
ETF’s with exposure to Achillion Pharmaceuticals, Inc. : May 11, 2016 May 11 2016
ACHILLION PHARMACEUTICALS INC Financials May 10 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... May 10 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 03 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 03 2016
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs May 03 2016
Achillion reports 1Q loss May 03 2016
Achillion reports 1Q loss May 03 2016
Achillion Reports First Quarter 2016 Financial Results and Provides Update on Clinical Programs May 03 2016
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 28 2016
Achillion to Present at the Deutsche Bank 41st Annual Health Care Conference Apr 28 2016
Can the Uptrend Continue for Achillion Pharmaceuticals (ACHN)? Apr 26 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 08 2016
Five Cheap Healthcare Stocks With Hedge Fund Support Mar 24 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Mar 14 2016
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Mar 03 2016
Achillion to Present at Two Upcoming Investor Conferences Mar 03 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 25 2016
ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 25 2016
Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE)... Feb 25 2016
Achillion beats Street 4Q forecasts Feb 25 2016
Achillion beats Street 4Q forecasts Feb 25 2016
Achillion Appoints Dr. Joel Barrish as Chief Scientific Officer Jan 04 2016
Achillion Appoints Dr. Frank Verwiel to Board of Directors Dec 16 2015
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of... Dec 05 2015
Achillion beats 3Q profit forecasts Nov 05 2015
Achillion Reports Third Quarter And Nine Month 2015 Financial Results Nov 05 2015
Achillion Announces Upcoming Oral Presentation at the 57th Annual Meeting of the American Society of... Nov 05 2015
Achillion Announces That Janssen Has Initiated a Phase 2a Study to Evaluate the Combination of... Oct 16 2015
Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week... Sep 17 2015
Achillion to Present at Two Upcoming Investor Conferences Sep 01 2015
Achillion Reports Second Quarter and Six Month 2015 Financial Results Aug 10 2015
Achillion reports 2Q loss Aug 10 2015
Achillion Announces That Janssen Has Initiated a Phase I Study to Evaluate the Effect of Simeprevir... Aug 03 2015
Achillion to Present at the JMP Securities Life Sciences Conference 2015 Jun 18 2015
Achillion reports 1Q loss May 07 2015
Achillion shares soar following update on hepatitis C drug Feb 09 2015
Achillion rises on new hepatitis C drug study Dec 22 2014
Achillion rises on new hepatitis C drug study Nov 10 2014
Achillion beats 3Q profit forecasts Nov 04 2014
Achillion rises on hepatitis C drug study Aug 15 2014

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)